Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID-19 tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted.